OGEN Oragenics
- 1.3800
- +0.1700+14.05%
- 1.3900
- +0.0100+0.72%
Oragenics News
Oragenics Inc Reports SEC Filing Update
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersNuwellis (NASDAQ:NUWE) shares rose 57.7% to $0.27 during Tuesday's regular session. The company's market cap stands at $4.1 million. As per the news, the Q1 earnings report came out today. Biov
Express News | Oragenics Shares Are Trading Higher After the Company Announced a Partnership With Avance Clinical to Conduct a Phase II Clinical Trial in Australia
Oragenics Partners With Avance Clinical for Phase II Concussion Trial in Australia
Oragenics Partners with Avance Clinical for Phase II Concussion Trial in Australia Download as PDF May 07, 2024SARASOTA, Fla., May 07, 2024 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGE
Earnings Week Ahead: Disney, Palantir, Shopify, Uber, Plug Power and More
Express News | Oragenics Inc - Company Has Begun to Prepare Its Plan of Compliance for Submission to NYSE American by May 18, 2024 Deadline
Oragenics, Inc. Announces Notification of Noncompliance With Additional NYSE American Continued Listing Standards
Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards Download as PDF April 19, 2024SARASOTA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NY
Oragenics, Inc. Files 10K and Provides Company Update
Oragenics, Inc. Files 10K and Provides Company Update Download as PDF April 01, 2024SARASOTA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (the "Company") (NYSE American: OGEN), a company focused on dev
Earnings Week Ahead: Walgreens Boots Alliance, Carnival, GameStop and More
Oragenics Appoints New CMO for Phase II TBI Drug Trial
Oragenics Appoints Kelly As Chief Medical Officer
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion Download as PDF March 18, 2024SARASOTA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (N
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion Download as PDF March 05, 2024SARASOTA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN), a company focus
Oragenics Inc Enhances Financial Standing With Equity Sale
Oragenics Announces Closing of Public Offering
Oragenics Announces Closing of Public Offering Download as PDF March 01, 2024SARASOTA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE American: OGEN) ("Oragenics" or the "Company"), a company focuse
Top Midday Decliners
Integral Ad Science (IAS) reported Q4 earnings Tuesday of $0.06 per diluted share, down from $0.07 a year earlier. Truist adjusted the price target on the company's shares to $17 from $26 while mainta
Express News | Oragenics Shares Are Trading Lower After the Company Announced the Pricing of a $2.1 Million Public Offering of 1.4 Million Shares at $1.50 per Share
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
GainersvTv Therapeutics (NASDAQ:VTVT) shares increased by 104.2% to $17.36 during Wednesday's pre-market session. The market value of their outstanding shares is at $35.3 million. Vivani Medical (NASD
Oragenics Shares Tumble Premarket After Stock Offering
By Colin Kellaher Shares of Oragenics slid more than 40% in premarket trading Wednesday after the development-stage biotechnology company said it was raising $2.1 million in a dilutive public offerin
Oragenics Inc Announces Proposed Public Stock Offering
Analysis
Price Target
No Data
